EW

PROSTHETICS EMERGENCY HEART VALVE

TAVR

SAPIEN 3 RESILIA HEART VALVE

INVENTORY SURGICAL ITEM

PROSTHETICS - HEART IMPLANTS

S3URCM26A, SAPIEN3 ULTRA RESILIA HEART VALVE 26MM

PROSTHETICS: TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) SURGICAL IMPLANTS RESTOCK

SURGICAL IMPLANTS

TAVR

TAVR HEART VALVES EXERCISE OPTION TWO.

Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Transitional Coverage for Emerging Technologies (TCET)/MCIT Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials (Health Equity Issues) Coverage with Evidence Development CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Heart Valve Disease Awareness Transcatheter Mitral Valve National Coverage Decision National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials (Health Equity Issues) Coverage with Evidence Development Tariffs

Coverage and reimbursement policy for medical devices/THV Medicare coverage of breakthrough therapies Policies promoting medical innovation. Coverage with evidence development. 21st Century Cures 2.0

Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue

Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders; Issues related to Senate Finance Dear Colleague process

Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development Japan Reimbursement of Medical Devices

Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue

Coverage and reimbursement policy for medical devices/THV Medicare coverage of breakthrough therapies Policies promoting medical innovation. Coverage with evidence development. 21st Century Cures 2.0

Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Expiring healthcare extenders

Corporate Tax Reform Proposals Tariffs Japan Reimbursement of Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development

Coverage and reimbursement policy for medical devices/THV Medicare coverage of breakthrough therapies Policies promoting medical innovation. Coverage with evidence development. 21st Century Cures 2.0